We hypothesized that plumbagin would reverse liver fibrosis in another way, through its accumulation in LSEC and subsequent amelioration of phenotype changes and dysfunction via decreasing profibrogenic factors, including ET-1 and VEGF, as well as reducing components of basement membrane LN and type IV collagen. Here, VEGFA is linked to Hepatic fibrosis.